Number needed to treat associated with ixekizumab and etanercept from UNCOVER-2 and UNCOVER-3 Phase III trials in the treatment of moderate-to-severe psoriasis

被引：0
|
作者：
Foster, S. [1 ]
Zhu, B. [1 ]
Burge, R. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2016年 / 136卷 / 05期
关键词：
D O I：
10.1016/j.jid.2016.02.177
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
150
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [1] Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
    Griffiths, Christopher E. M.
    Reich, Kristian
    Lebwohl, Mark
    van de Kerkhof, Peter
    Paul, Carle
    Menter, Alan
    Cameron, Gregory S.
    Erickson, Janelle
    Zhang, Lu
    Secrest, Roberta J.
    Ball, Susan
    Braun, Daniel K.
    Osuntokun, Olawale O.
    Heffernan, Michael P.
    Nickoloff, Brian J.
    Papp, Kim
    LANCET, 2015, 386 (9993): : 541 - 551
  • [2] Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)
    Reich, Kristian
    Leonardi, Craig
    Lebwohl, Mark
    Kerdel, Francisco
    Okubo, Yukari
    Romiti, Ricardo
    Goldblum, Orin
    Dennehy, Ellen B.
    Kerr, Lisa
    Sofen, Howard
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2017, 28 (04) : 282 - 287
  • [3] Impact of ixekizumab treatment on sexual function in moderate-to-severe psoriasis patients: 12 week results from two phase 3 trials UNCOVER-2 and UNCOVER-3
    Guenther, Lyn
    Sofen, Howard
    Cathers, Jennifer
    Poulin, Yves P.
    Lebwohl, Mark
    Bleakman, Alison Potts
    Zhu, Baojin
    Nikai, Enkeleida
    van de Kerkhof, Peter
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB254 - AB254
  • [4] Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)
    Menter, A.
    Warren, R. B.
    Langley, R. G.
    Merola, J. F.
    Kerr, L. N.
    Dennehy, E. B.
    Shrom, D.
    Amato, D.
    Okubo, Y.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (10) : 1686 - 1692
  • [5] Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3
    Egeberg, Alexander
    Wu, Jashin J.
    Korman, Neil
    Solomon, James A.
    Goldblum, Orin
    Zhao, Fangyi
    Mallbris, Lotus
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (01) : 104 - +
  • [6] Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes
    Puig, Luis
    Dossenbach, Martin
    Berggren, Lovisa
    Ljungberg, Anders
    Zachariae, Claus
    ACTA DERMATO-VENEREOLOGICA, 2019, 99 (11) : 971 - 977
  • [7] Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
    Andrew Blauvelt
    Kim A. Papp
    Christopher E. M. Griffiths
    Luis Puig
    Jamie Weisman
    Yves Dutronc
    Lisa Farmer Kerr
    Dapo Ilo
    Lotus Mallbris
    Matthias Augustin
    American Journal of Clinical Dermatology, 2017, 18 : 273 - 280
  • [8] A Phase 3 Trial Comparing Ixekizumab with Placebo and Etanercept for Moderate-to-Severe Plaque Psoriasis: Results from the 12 Week Induction Period of UNCOVER-2
    Griffiths, C. E. M.
    Leutz, A.
    Reich, K.
    Lebwohl, M.
    van de Kerkhof, P.
    Paul, C.
    Menter, A.
    Cameron, G. S.
    Erickson, J.
    Zhang, L.
    Secrest, R.
    Ball, S.
    Braun, D.
    Osuntokun, O. O.
    Heffernan, M.
    Nickoloff, B. J.
    Papp, K.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 3 - 3
  • [9] Improvements in fingernail lesions in patients with moderate-to-severe psoriasis treated with ixekizumab versus placebo and etanercept: Results from UNCOVER-2
    van de Kerkhof, Peter
    Guenther, Lyn
    Gottlieb, Alice
    Sebastian, Michael
    Wu, Jashin J.
    Foley, Peter
    Morita, Akimichi
    Goldblum, Orin
    Kerr, Lisa
    Rich, Phoebe
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB255 - AB255
  • [10] Ixekizumab impact on itch severity compared to etanercept and placebo: Results from UNCOVER-2, a phase 3 trial in patients with moderate-to-severe plaque psoriasis
    Kimball, Alexa Boer
    Nikai, Enkeleida
    Zhu, Baojin
    Carlier, Hilde
    Yosipovitch, Gil
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S19 - S19
12345